Instituto de Parasitología y Biomedicina López-Neyra, C.S.I.C., Granada.
Clin Exp Rheumatol. 2011 Jan-Feb;29(1):19-25. Epub 2011 Feb 23.
To assess the influence of the RETN rs1862513 polymorphism in the risk of cardiovascular (CV) disease and subclinical atherosclerosis in patients with rheumatoid arthritis (RA).
Six hundred and sixty-eight patients fulfilling the 1987 American College of Rheumatology classification criteria for RA, seen at the rheumatology outpatient clinics of Hospital Xeral-Calde, Lugo, and Hospital San Carlos, Madrid, Spain, were studied. Patients were genotyped for the RETN rs1862513 polymorphism using predesigned TaqMan single nucleotide polymorphism genotyping assay. Also, HLA-DRB1 genotyping was performed using molecular based methods. Carotid intima-media thickness (IMT), flow-mediated endothelium-dependent and endothelium independent vasodilatation, used as surrogate markers of subclinical atherosclerosis, were measured in a subgroup of patients.
No significant differences in the genotypic or in the allelic distribution between RA patients with or without CV disease were found. In this regard, we only observed a slight increased frequency of homozygous and heterozygous for the minor allele G (CG+GG genotypes) among patients who experienced CV events compared to those without CV events (53.04% vs. 52.62%, p=0.94). A higher frequency of classic CV risk factors was observed among the carriers of the minor allele G. However, in the adjusted logistic regression model no association between the RETN variant and CV disease was found (p=0.50). Also, when surrogate markers of subclinical atherosclerosis were assessed, in the adjusted ANCOVA model only a trend towards a higher carotid IMT was found among allele G carriers (p=0.06).
RETN rs1862513 polymorphism does not seem to be a genetic risk factor for both clinically evident CV disease and subclinical atherosclerosis in patients with RA.
评估 RETN rs1862513 多态性在类风湿关节炎（RA）患者心血管（CV）疾病和亚临床动脉粥样硬化风险中的影响。
研究了西班牙卢戈 Xeral-Calde 医院和马德里 San Carlos 医院的风湿病门诊就诊的 668 名符合 1987 年美国风湿病学院分类标准的 RA 患者。使用预设计的 TaqMan 单核苷酸多态性基因分型检测评估 RETN rs1862513 多态性。还使用基于分子的方法进行 HLA-DRB1 基因分型。在亚组患者中测量颈动脉内膜中层厚度（IMT）、血流介导的内皮依赖性和非依赖性血管舒张，作为亚临床动脉粥样硬化的替代标志物。
RA 患者中 CV 疾病组与无 CV 疾病组在基因型或等位基因分布上无显著差异。在这方面，与无 CV 事件的患者相比，发生 CV 事件的患者中纯合子和杂合子 minor 等位基因 G（CG+GG 基因型）的频率略有增加（53.04% vs. 52.62%，p=0.94）。携带 minor 等位基因 G 的患者中经典 CV 危险因素的频率更高。然而，在调整后的逻辑回归模型中，RETN 变体与 CV 疾病之间没有关联（p=0.50）。此外，当评估亚临床动脉粥样硬化的替代标志物时，在调整后的 ANCOVA 模型中，仅发现等位基因 G 携带者的颈动脉 IMT 呈升高趋势（p=0.06）。
RETN rs1862513 多态性似乎不是 RA 患者临床明显 CV 疾病和亚临床动脉粥样硬化的遗传危险因素。
